Orchestra BioMed Holdings, Inc. OBIO
At closeNov 6, 2026, 4:00 AM EST
Pre-market · Nov 6, 4:00 AM ET
- YTD
- +35.42%
- 1 year
- +43.37%
- Market cap
- 337.79M
- Revenue (ttm)
- 2.65M
- EPS (ttm)
- -0.86
- Shares out
- 37.82M
- Forward P/E
- -2.66
- YTD return
- +35.42%
- 1-year return
- +43.37%
- Volume
- 253.75K
- Avg volume
- 343.85K
- Open
- 6.00
- Previous close
- 6.00
- Day's range
- 5.60 – 6.00
- 52-week range
- 3.46 – 6.50
- Beta
- 0.41
- Price target
- 15.60 (+177.6%)
- Earnings date
- Aug 12, 2024
3M +1.47 (+35.42%)
Key statistics
- Enterprise value
- 121.94M
- PEG ratio
- 0.00
- Price / sales
- 67.35
- Price / book
- 3.85
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 135.60%
- Free cash flow
- -24.41M
- Total cash
- 66.93M
- Total debt
- 1.84M
- Return on equity
- -91.66%
- Short % of float
- 3.63%
- 50-day average
- 5.55
- 200-day average
- 5.90
Analyst view
- Target (low)
- 14.00
- Target (mean)
- 15.60
- Target (high)
- 20.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.425.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.44 | -0.41 | +0.03 | +6.82% |
| Aug 12, 2024 | Jun 1, 2024 | -0.41 | -0.45 | -0.04 | -9.76% |
| Aug 12, 2024 | Jun 1, 2024 | -0.41 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.40 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.40 | -0.38 | +0.02 | +5.00% |
| Mar 27, 2024 | Dec 1, 2023 | -0.38 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 13, 2024 | Chardan Capital | main | Buy | Buy |
| Aug 22, 2024 | HC Wainwright & Co. | init | — | Buy |
| Jul 25, 2024 | B. Riley Securities | init | — | Buy |
| Jun 12, 2024 | Chardan Capital | reit | Buy | Buy |
| Mar 28, 2024 | Chardan Capital | main | Buy | Buy |
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- orchestrabiomed.com
News
Your note
Sign in to keep a note on OBIO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARYEH JASON M | Director | Stock Award(Grant) | Jun 19, 2024 | 68,360 |
| CONNEALY PAMELA ANN | Director | Stock Award(Grant) | Jun 19, 2024 | 21,289 |
| FAIN ERIC S | Director | Sale | Sep 9, 2024 | 0 |
| HOCHMAN DAVID P | Chief Executive Officer | Purchase | Dec 17, 2024 | 919,640 |
| LITTLE WILLIAM REED | Officer | Purchase | May 29, 2024 | 307,859 |
| MIKA YUVAL | Officer | Stock Award(Grant) | May 7, 2024 | 158,905 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RTW Investments LP | 21.59% | 8,206,159 | 38.49M | Sep 29, 2024 |
| Perceptive Advisors Llc | 12.08% | 4,592,556 | 21.54M | Sep 29, 2024 |
| Blackrock Inc. | 5.11% | 1,942,391 | 9.11M | Sep 29, 2024 |
| Vanguard Group Inc | 3.45% | 1,309,803 | 6.14M | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.49% | 567,219 | 2.66M | Sep 29, 2024 |
| Price (T.Rowe) Associates Inc | 1.35% | 512,663 | 2.40M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.84% | 698,140 | 3.27M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.37% | 520,424 | 2.44M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.09% | 414,591 | 1.94M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 0.91% | 344,985 | 1.62M | Sep 29, 2024 |
| Blackrock Funds-Health Sciences Opportunity Portfolio | 0.69% | 262,308 | 1.23M | Aug 30, 2024 |
| Fidelity Small Cap Index Fund | 0.63% | 237,956 | 1.12M | Aug 30, 2024 |